

**PEQG26**

Population, Evolutionary and  
Quantitative Genetics Conference



**ID: 474**

# **How Cancer Cells Undergoing a Treatment Course Evolve to Survive Multiple Mass Extinctions**

Adam Cheong  
Proof School

Mark Cheong  
UC Berkeley

Paul Fong  
Duke University

# ABSTRACT

---

The vast diversity of genetic and phenotypic characteristics observed in human cancers, according to Hanahan (2026), can be understood in the context of how cancers arise via multistep pathways of tumorigenesis that lead to the formation of primary tumors, which subsequently evolve and progress due to selective advantage in the face of multifaceted barriers to continuing proliferative expansion, resulting in metastasis and adaptive resistance.

Here we elucidate the adversarial viewpoint: a *press-pulse* framework borrowed from paleobiology (Arens & West, 2008) for modeling therapeutic intervention targeted at the primary tumor, whose microenvironment undergoes *terraforming* and subsequently becomes unfit for cancer cells proliferation, leading to multiple *mass extinctions* over the course of cancer treatment, finally resulting in remission as the residual cancer cells turn quiescent.

The population dynamics driven by tumor growth vs. dose response is captured in our proposed model, as the cancer cells population follows a Gompertzian growth curve after metabolic reprogramming but shrinks in response to drug treatment. To shrink a tumor over multiple treatment cycles, dose responses are modeled as the outcome of catastrophic events decimating cancer cells as intravenous antibody-drug conjugate (Madhusoodanan, 2024) diffuses across blood vessel walls and penetrates the tumor, driven by concentration gradient according to Fick's laws.

Tumoral evolution within our framework offers mechanistic insights into the structure of a shifting fitness landscape characterized by the selective pressure of dose responses on residual regrowth. We illustrate how residual subpopulations of cancer cells evolve to survive multiple mass extinctions originated from a prescribed course of antibody-drug conjugate targeting the primary tumor, potentially laying the seeds for future metastasis or adaptive resistance in the unfortunate event of a relapse. We propose to construct a simulation testbed to further explore this key insight of population dynamics.

---

# INTRODUCTION

## Antibody-Drug Conjugates Show Superior Response when Dosed at MTD




Fig. 1: Antibody-Drug Conjugate (ADC) <sup>[4]</sup>

Image Credit: Drago & Norton (2021)

Over the last two decades, an increasing number of antibody-drug conjugates (ADCs) have been approved for cancer treatment, broadening therapeutic options for patients beyond traditional small molecule drugs. Through their unique mode of action as “*magic bullets*”, these targeted therapies hold the promise of redressing the poor balance between *safety* and *efficacy* with traditional chemotherapy <sup>[4, 6]</sup>.

The “sweet spot” between the lowest concentration that produces a desired therapeutic effect (minimum effective dose or MED) and the concentration just before toxicity kicks in (maximum tolerated dose or MTD) is called the *therapeutic window*.

When dosed at or near MTD, ADCs display improved efficacy over small molecules in trials. Across the board, ADCs have already achieved greater beneficial outcomes for patients compared with traditional chemotherapy. The *objective response rates* (ORR) of ADC treatments frequently score above 40 percent in breast, gastric, urothelial, and lung cancer trials where small molecules rarely exceed 25 percent <sup>[2, 8]</sup>.




Fig. 2: Mechanism of Action for Antibody-Drug Conjugates <sup>[4]</sup>

# RESEARCH QUESTION

## How to Make a Tumor Microenvironment “Most Unfit” Under Press-Pulse?

Four forces that drive cancer cells population dynamics:

(a) **Tumor Growth:** proliferative cancer cells harness aerobic glycolysis to generate energy rapidly to drive tumor growth;

(b) **Pulse Therapy:** dose responses are the outcome of catastrophic events decimating cancer cells as intravenous drug diffusing across blood vessel walls penetrates the tumor;

(c) **Somatic Mutation:** somatic mutation during residual regrowth in between treatment cycles selects for drug-resistant cells that drive future cancer recurrence; and

(d) **Press Therapy:** chronic microenvironmental stress (e.g., energy deprivation from starvation of glucose) slows down cell cycles and reduces cancer cells population resistance.

**Note:** Cancer cells compete for resources in order to grow rapidly, while evading counterattacks. Mathematical models of tumoral evolution describe how cancer cell populations grow with aerobic glycolysis but shrink under drug treatment, just as Lotka-Volterra equations describe the population dynamics of snowshoe hares and the lynx that feed upon them. New complexity in population dynamics arises when somatic mutation across treatment cycles and metabolic intervention are introduced and added to the model.



Fig. 3: Terraforming a tumor microenvironment under press-pulse.

# METHODS — Tumor Growth

## Modeling Tumor Growth with a Gompertzian Curve





Fig. 4: **Gompertzian tumor growth:** initial growth at the inflection point appeared exponential, before slowing to approach the asymptote (i.e., asymmetric sigmoid curve).

# METHODS — Pulse Therapy

## 1. Dose at Maximal Effective Concentration — Dependent on Size of Tumor




Fig. 5: Fick's laws describe diffusion driven by a concentration gradient, from high-concentration intravenous space to low-concentration intercellular space.

$$J = -D \frac{d\phi}{dx}$$

Fick's 1st law

where

- $J$  is the diffusion flux, which measures the amount of substance flowing through a unit area during a unit time interval,
- $D$  is the diffusion coefficient, or diffusivity, in area per unit time.

$$\frac{d\phi}{dx} = \frac{1}{x^2}$$

Concentration gradient formula

# METHODS — Pulse Therapy

## 2. Compute Dose Response Curve — for Each Tumor Size and Shape




Fig. 6: **Cross-sectional view:** depth of diffusion into a tumor determines effective concentration of dose.




Fig. 7: **Dose response curve** computed based on cancer cell population reachable at each tumor depth.

# METHODS — Pulse Therapy

## 3. Adjust Dose Response Model — as Concentration Decreases Over Time

$$\text{Exposure Time} = t_1 - t_0$$

$$\frac{\partial \phi}{\partial t} = D \frac{\partial^2 \phi}{\partial x^2}$$

Fick's 2nd law




Fig. 8: **Changing concentration:** ensure tumor periphery at  $d$  has enough exposure time ( $t_1 - t_0$ ) by working backwards to set maximal effective concentration at  $EC_{max}^+$ .




Fig. 9: Dose response model adjusted for maximal effective concentration (at  $EC_{max}^+$ ).

# METHODS — Somatic Mutation

## Cancer Cells Evolve in Between Treatment Cycles to Survive Mass Extinctions




Fig. 10: **Residual regrowth** in between treatment cycles selects for drug-resistant cells that drive future cancer recurrence.

Would starving *proliferative* cancer cells of glucose improve dose response for cancer patients?

Could one switch to a *reduced dose* regimen without compromising dose response by going on a calorie-restricted diet to bring down the glucose level, which slows down the cell cycle and makes proliferative cancer cells more vulnerable?

It follows that one could then apply a *denser* dose schedule to suppress residual regrowth while also shortening treatment cycles.

Reduced heterogeneity in the tumor would then make relapse less likely, thus maximizing disease-free survival (DFS) for cancer patients.

# METHODS — Press Therapy

## Bioenergetic Intervention Makes Proliferative Cancer Cells Vulnerable






Fig. 11: **Proliferative cancer cell cycle:** glucose restriction can cause cancer cells to stay in G1 phase longer (or become quiescent), so cell-cycle (S/G2/M) targeting drug has ample time to enter cancer cells before the start of its targeted phase (e.g., to disrupt DNA synthesis), thus improving dose response.

### Option A: Hit cancer cell *faster*



... with heavier dose?

### Option B: *Slow down* target cell cycle



... by limiting glucose!

Fig. 12: **Epiphany:** either: (A) magic bullet moves *faster* to hit cancer cells with heavier dose of ADC at a higher concentration gradient; or (B) we *slow down* target cell cycle awaiting magic bullet arrival.

# CONCLUSIONS

## A Denser Dose Schedule Minimizes Somatic Mutation Across Treatment Cycles




Fig. 13: Residual regrowth between treatment cycles drives somatic mutation: (A) high residual regrowth fails to shrink primary tumor, (B) baseline residual regrowth shrinks primary tumor but neglects somatic mutation, (C) low residual regrowth under press therapy reduces somatic mutation, and (D) least residual regrowth under press therapy minimizes somatic mutation with a *denser* dose schedule.

# FUTURE WORK

## Safer ADC Regimens That Also Maximize Disease-Free Survival?




Fig. 14: Chain-of-thought reasoning for our research design.

We propose that tumor size and bioenergetics together determine dose response, which we see as multifaceted and not simply a static curve as commonly believed. Importantly, a cancer patient can improve dose response with nutritional intervention under one's control.

Our ongoing research has therapeutic implications: a *safer* ADC regimen realized through improved dose response modeling benefits not just late-stage cancer patients considering palliative care, but also early-stage cancer patients seeking alternative treatment paths that maximize long-term *disease-free survival* [3].

By taking a longer view of DFS as an alternate endpoint, we hope to optimize *safety* and *efficacy* together by limiting residual regrowth during treatment — unlike traditional chemotherapy preoccupied with maximizing cell kill in the primary tumor, sacrificing safety.

# REFERENCES

---

1. Arens, N. C., & West, I. D. (2008). Press-pulse: a general theory of mass extinction? *Paleobiology*, *34*(4), 456–471.
2. Aykan, N. F., & Özatlı, T. (2020). Objective response rate assessment in oncology: Current situation and future expectations. *World Journal of Clinical Oncology*, *11*(2), 53–73.
3. Delgado, A., & Guddati, A. (2021). Clinical endpoints in oncology — a primer. *Am J Cancer Res*, *11*(4), 1121–1131.
4. Drago, J., & Norton, L. (2021, September). Implication of Cancer Growth Kinetics for the Further Development of Antibody-Drug Conjugates. *DIA Global Forum*.
5. Hanahan, D. (2026). Hallmarks of cancer—Then and now, and beyond. *Cell*, *189*.
6. Madhusoodanan, J. (2024, March 1). These cancers were beyond treatment—but might not be anymore. *Scientific American*.
7. Michor, F., & Beal, K. (2015). Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. *Cell*, *163*(5), 1059–1063.
8. Mocny, J., Dieterich, P., & Glassford, I. (2023, July 4). Antibody Drug Conjugates: windows of opportunity. *Drug Target Review*.
9. Scibilia, K. R., Gallagher, K., Masud, M. A., Robertson-Tessi, M., Gatenbee, C. D., West, J., Llamas, P., Prabhakaran, S., Gallaher, J., & Anderson, A. R. A. (2025). Mathematical Oncology: How Modeling Is Transforming Clinical Decision-Making. *Cancer Research*, *85*(24), 4866–4879.
10. Seyfried, T. N., Yu, G., Maroon, J. C., & D’Agostino, D. P. (2017). Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. *Nutrition & Metabolism*, *14*(1).
11. Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. *Nature*, *575*(7782), 299–309.